Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — InfuSystem Holdings — Investor Presentation (March 2021)
22 slides from Infusystems's investor presentation, Mar 26, 2021
Slide 1: Enabling Continuity of Care for Patients, From the Clinic to Their Home
System’ SAFE. SMART. TRUSTED” Enabling Continuity of Care for Patients, From the Clinic to Their Home Investor Presentation March 2021 | (NYSE American: INFU)
Slide 2: Forward-Looking Statement / Non-GAAP Measures
Forward-Looking Statement / Non-GAAP Measures Forward-Looking Statement Certain statements contained inthis presentation are forward-looking statements ‘thin the meaning of Section 27A ofthe Securities ct of 1933, as amended, and Section 21E ofthe Secures Exchange Act of 1934, as amended, suchas sta
Slide 3: Investment Highlights
Investment Highlights Double-digit growth through two proven business platforms: Durable Medical Equipment (DME) and Integrated Therapy Services (ITS) arket data as of 3/22/21 ae EQ WY Providing best-in-class durable medical equipment and clinic-to-home care $10BNorth American Home DME market; growt
Slide 4: Focus, Scale and Experience
Focus, Scale and Experience @ Leading North American provider of equipment and services with 100K+ device fleet ©@ 34ear history, perfected model in Oncology and now expandinginto multiple therapies @ ‘six major service areas in the U.S. and Canada with nearly 300 employees ©@ National scale, servin
Slide 5: Two Proven Business Platforms
Two Proven Business Platforms Growth Driven by Market Share Gains and New Therapy Opportunities DME $36.3M (37%) DURABLE MEDICAL EQUIPMENT (DME) SUPPORT SERVICES Equipment and consumable sales/lease to hospitals, clinics and home infusion providers Total 2020 Revenue: $97.4 Million ITS $61.1M (63%)
Slide 6: Well-Diversified & Strategic Payer Relationships
Well-Diversified & Strategic Payer Relationships Percentage of Cash Collected by Payer 2019 Medicare and gi Medicaid CMS: 1.1% Private Pay: 2.4% ~ 6,500 Direct Pay Hospital and Alternate Site Customers Hospital/Alternate piteiDirect Payzi88.8%6 Commercial Payer: 47.7% No Single Payer Greater Than 10
Slide 7: DME Platform
DME Platform Traditional Medical Distribution, Lower-Margin, High-Turn Model Source Devices = ~ Device Repair & o* p bles to Maintenance I © Pump rentals and VAR sales (new devices) @ Broker/trader sales (used devices) @ Biomedical service and repair @ Direct payer model: INFU is paid directly by th
Slide 8: ITS Platform
ITS Platform Unique and Scalable, High-Margin, High-Service Model Clinical Sup Support/ Logistics B Device Repair & Maintenance © supply medical equipment and proprietary consumables for outpatient care @ Hospital, clinician and patient customer service @ Third-party payer model: INFU is paid by the
Slide 9: Competitive Advantages
Competitive Advantages Significant Barriers to Entry Based on Unique Focus, National Scale and Established Payer Network ri Cliniéal Ca continuous pat and improv Patient Safety avent Payercontracts ly InfuSystem Mobiles the only patient app ath facilitating two-way patient and clinical team | ate ‘c
Slide 10: Growth Strategy of ITS Platform
Growth Strategy of ITS Platform ‘Adding New High-Margin Therapy Segments Go-to-Market Evaluation Strategy Growth/Traction Established Oncology Pain Management Negative Pressure Wound Therapy Future Therapies _>- $874 million 2020 revenue multiple therapies through __— Over $900 million current on wi
Slide 11: Highly Scalable Existing Infrastructure
Highly Scalable Existing Infrastructure Foundation Built In Oncology: Leverage lt Multiple New Therapies Can Be Added With Times (Pain, NPWT, Future Therapies) Minimal Incremental Expense Oncology & Pain Management NPWT Offices and Logistics Future Therapies 34 Years of Experience, Know-How, and Rep
Slide 12: ITS Model: Platform Proven in Oncology
ITS Model: Platform Proven in Oncology InfuSystem ITS Value Proposition Opportunity: Oncology Home Treatment @ * Large capital expense for clinics in addition to maintenance and nightly triage + Reduced staff available to help patients with infusion pump questions and billing Solution: Outpatient Tr
Slide 13: Fourth Quarter Financial Results
Fourth Quarter Financial Results Net Revenue Net Income AEBITDA” Op Cash Flow (1) See Appendix 8 ‘SAFE, SMART. TRUS} 2020 2019 2020 2019 2020 2019 2020 2019 RE s2a.7m $21.71 EEE $10.7 Bf sosm HEE «<6.2u ME 5.4m EEE 7.0m GE S431
Slide 14: Full Year Financial Results
Full Year Financial Results MM 897- Net Revenue ey Sa74M 2019 Ts S211 kT 17.3M Net Income (loss) 2020 . 2019 I $1.4m “ 2020 MEE $26.2 AEBLIDA 2019 A $12.21 2020 MEE $20.3m Op Cash Flow 2019 MEE si3.0m (1) See Appendix 8 SMART. TRUSTED,
Slide 15: Financial Trend & Current 2021 Guidance
Financial Trend & Current 2021 Guidance Net Revenues'”) & AEBITDA) $1070. $1100 75.0630. i & 2 Guo s)vauiey 20178 2018 20198 20208, one (ama tter Aaa 1. 2017 consoidatedrevenueshave been adjustetoreflettheetectoftheadoptionof ASC6O6 i201. 2. Seedppenics o ; VART. TRUSTED. (ThfuSystem
Slide 16: Financial Trend & Current Targets
Financial Trend & Current Targets (buon) Cash Flows From Operations 240 sas saio-s2a0 | ssa 3.0% gas so ask Ss S30 mom pees gs 3% Sos 70% 20 2s 1538 se om on 125% as 90 no 20178 20188 20198, 20208 ote SruDn9y 29N 40 CinfuSystem
Slide 17: Recent Accomplishments & Corporate Priorities
Recent Accomplishments & Corporate Priorities Dominant market share and sales increases In oncology home therapy market — Late 2018/2019 Proactive patient engagement initiative launched to improve revenue cycle management — Qi 2020 Entered negative pressure wound therapy market with partner, Cardina
Slide 18: Executive Team
Barry Steele - Excite Vee Present Cate Lachance, BSN RN, ORM — Present chit Fane Ofer ‘chet Operating Ofer fchard io he xeetve ofr & Executive Team EX Seasoned Industry Experience, Including: Pharmaceutical, Health Care, Life Sciences, Automotive OEM, Public Medical Devi Accounting, Military, Retail
Slide 19: Summary
Summary care from the clinic into the home, driving double-digit > ‘Two proven platforms that enable the delivery of patient revenue, cash flow growth and accelerating profit Market opportunities driven by rising health care costs, an aging population, medical innovation, patient satisfaction and ot
Slide 20: Questions & Answers
infuSystem SAFE. SMART. TRUSTED? Questions & Answers © | SAFE.SMART. TRUSTED.
Slide 21: Appendix A - GAAP to Non-GAAP Reconciliation
Appendix A- GAAP to NON-GAAP Reconciliation [NETINCOME (1055) 7 ADJUSTED EBITDA: ‘Twelve Months Ended ‘Tivee Months Ended ‘December 3, December 31, (inthousonds) 7217 21s 2018 2020 219 72020 ‘GAAP net income 8) 20,707) (035) ——aaen «8a 305 «10,670 Adjustments Interest expense 1332 a0 19081255 468 23
Slide 22: Appendix B - Select Balance Sheet Data
Appendix B — Select Balance Sheet Data December 31, December 31, 2019 2020 (toThowsands, xceptshare Data) Cash and Cash Equivalents $2,647 $9,648 Available Liquidity 21,258 19,685 Working Capital, Less Cash & Debt 2,893, 6,549 Medical Equipment, Net 33,225 35,611 Total Assets 79,224 96,991 Total Deb
InfuSystem Holdings — Investor Presentation (March 2021) on 6ix